MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Authors: Marc S Raab, Monika Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor W Blau, Hermann Einsele, Barbara Ferstl, Natalie Schub, Christoph Röllig, Katja Weisel, Mark Winderlich, Janine Griese, Stefan Härtle, Johannes Weirather, Tiantom Jarutat, Christian Peschel, Manik Chatterjee

Published: 2020-03-12

DOI: 10.1016/s2352-3026(19)30249-2

Source: Full article

---

Abstract

No abstract found.